Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q4 FY20 results · Jan–Mar 2020
Bliss GVS Pharma reported revenue from operations of ₹119.80 crore (down 50.9% from Q4 FY19) and net profit of ₹5.57 crore (down 70.3% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.80 | 244.05 | −50.9% | 147.85 | −19.0% |
| Other income | 16.60 | 2.79 | +495.2% | 5.52 | +200.8% |
| Total income | 136.40 | 246.84 | −44.7% | 153.37 | −11.1% |
| Profit before tax | 13.33 | 31.60 | −57.8% | 34.41 | −61.3% |
| Net profit for the period | 5.57 | 18.79 | −70.3% | 25.45 | −78.1% |
| Attributable to shareholders of the company | 8.75 | 18.11 | −51.7% | 23.75 | −63.2% |
| EPS, basic (₹) | 0.85 | 1.76 | −51.7% | 2.30 | −63.0% |
| Net margin (%) | 4.7 | 7.7 | 17.2 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 97.97 | 106.14 | −7.7% | 124.82 | −21.5% |
| Other income | 15.24 | 3.02 | +404.9% | 5.61 | +171.5% |
| Total income | 113.21 | 109.16 | +3.7% | 130.43 | −13.2% |
| Profit before tax | 23.53 | 14.86 | +58.3% | 31.56 | −25.5% |
| Net profit for the period | 16.42 | 4.64 | +253.9% | 23.56 | −30.3% |
| EPS, basic (₹) | 1.59 | 0.45 | +253.3% | 2.28 | −30.3% |
| Net margin (%) | 16.8 | 4.4 | 18.9 |
Consolidated
- Filed with BSE
- 17 Jun 2020, 20:30 IST
- Board meeting
- 16 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Jun 2020, 20:30 IST
- Board meeting
- 16 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE